Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.72 |
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 5/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659469 | 0.97 | HTR1A (0.67) | HTR1ADRD2CACNA1GMEN1LMNA | |
| SCHEMBL5654643 | 0.89 | HTR1A (0.66) | HTR1ADRD2CACNA1GLMNAMAPT | |
| SCHEMBL5656689 | 0.85 | MAPT (0.62) | HTR1ADRD2CACNA1GMEN1LMNA | |
| SCHEMBL5655720 | 0.84 | HTR1A (0.69) | HTR1ADRD2CACNA1GLMNAMAPT | |
| SCHEMBL4636850 | 0.84 | HTR1A (0.69) | HTR1ADRD2MEN1KMT2AHTR7 | |
| SCHEMBL5659051 | 0.83 | HTR1A (0.57) | HTR1ADRD2MEN1LMNAMAPT | |
| SCHEMBL5657814 | 0.82 | MAPT (0.64) | HTR1ADRD2CACNA1GMEN1LMNA | |
| SCHEMBL5658350 | 0.81 | HTR7 (0.64) | HTR1ADRD2LMNAMAPTHTR7 | |
| SCHEMBL4636812 | 0.81 | HTR1A (0.65) | HTR1ADRD2HTR7 | |
| SCHEMBL5658140 | 0.79 | PTPN11 (0.55) | HTR1ADRD2CACNA1GMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223765-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | disclosed |
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1464641-A1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | H. Lundbeck A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | OPRD1, VDR, GPR4 | HTR1A 331/4885DRD2 27/4885CACNA1G 1435/4885 |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | OPRD1, DRD3, DRD2 | HTR1A 81/4885DRD2 3/4885CACNA1G 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.